Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078083 | 0.81 | KDM4E (0.42) | KDM4EAURKARPS6KB1LMNABAZ2B | |
| SCHEMBL6078641 | 0.78 | AURKA (0.56) | KDM4EAURKARPS6KB1LMNABAZ2B | |
| SCHEMBL6078187 | 0.77 | CNR1 (0.45) | KDM4EAURKARPS6KB1LMNABAZ2B | |
| SCHEMBL22844156 | 0.76 | AURKA (0.41) | KDM4EAURKARPS6KB1LMNABAZ2B | |
| SCHEMBL6078075 | 0.74 | TSHR (0.48) | KDM4EAURKARPS6KB1LMNABAZ2B | |
| SCHEMBL6079097 | 0.74 | GRN (0.49) | KDM4EAURKARPS6KB1ALDH1A1POLB | |
| SCHEMBL6078318 | 0.72 | TSHR (0.39) | KDM4EAURKARPS6KB1LMNABAZ2B | |
| SCHEMBL357627 | 0.71 | BAZ2B (0.63) | KDM4ELMNABAZ2BALDH1A1CYP1A2 | |
| SCHEMBL6077004 | 0.71 | DUT (0.35) | KDM4EAURKARPS6KB1LMNABAZ2B | |
| SCHEMBL17324801 | 0.70 | AURKA (0.52) | AURKARPS6KB1LMNAPOLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045619-B2 | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-05-16 | — | — | US | disclosed |
| US-20030166923-A1 | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. | 2003-09-04 | — | — | US | disclosed |
| EP-0725783-B1 | 2-(PYRAZOL-3-YL)CARBAPENEM DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2002-12-18 | — | — | EP | disclosed |
| US-20020147333-A1 | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. | 2002-10-10 | — | — | US | disclosed |
| CN-1167486-A | 2- (pyrazol-3-yl) carbapenem derivatives | SMITHKLINE BEECHAM PLC (GB) | 1997-12-10 | — | — | CN | disclosed |
| US-5612477-A | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C | 1997-03-18 | — | — | US | disclosed |
| US-5606051-A | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147333-A1 | 2-(pyrazol-3-yl)carbapenem derivatives | DPEP1, DHPS, JMJD6 | KDM4E 154/4885AURKA 2407/4885RPS6KB1 143/4885 |
| US-20030166923-A1 | 2-(pyrazol-3-yl)carbapenem derivatives | DHPS, DPEP1, JMJD6 | KDM4E 149/4885AURKA 2595/4885RPS6KB1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.